Advertisement
BGLAF
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BGLAF’s FA Score shows that 2 FA rating(s) are green while.
- BGLAF’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BGLAF’s TA Score shows that 2 TA indicator(s) are bullish.
- BGLAF’s TA Score: 2 bullish, 2 bearish.
Price Growth
BGLAF (@Pharmaceuticals: Generic) experienced а 0.00% price change this weekfor the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.55%. For the same industry, the average monthly price growth was +67.47%, and the average quarterly price growth was +80.21%.
Industries' Descriptions
@Pharmaceuticals: Generic (+1.55% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| BGLAF | |
| Capitalization | 1.13B |
| EBITDA | 393M |
| Gain YTD | 8.768 |
| P/E Ratio | 35.10 |
| Revenue | 1.44B |
| Total Cash | 622M |
| Total Debt | N/A |
| BGLAF | |
|---|---|
| RSI ODDS (%) | 3 days ago 50% |
| Stochastic ODDS (%) | 2 days ago 33% |
| Momentum ODDS (%) | N/A |
| MACD ODDS (%) | 2 days ago 33% |
| TrendWeek ODDS (%) | 2 days ago 24% |
| TrendMonth ODDS (%) | 2 days ago 24% |
| Advances ODDS (%) | N/A |
| Declines ODDS (%) | N/A |
| BollingerBands ODDS (%) | N/A |
| Aroon ODDS (%) | 2 days ago 21% |
Advertisement
BGLAF and Stocks
Correlation & Price change
A.I.dvisor tells us that BGLAF and SNOA have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BGLAF and SNOA's prices will move in lockstep.
| Ticker / NAME | Correlation To BGLAF | 1D Price Change % | ||
|---|---|---|---|---|
| BGLAF | 100% | N/A | ||
| SNOA - BGLAF | 30% Poorly correlated | -2.41% | ||
| CTTH - BGLAF | 28% Poorly correlated | N/A | ||
| SHPH - BGLAF | 8% Poorly correlated | -0.60% | ||
| SDZXF - BGLAF | 5% Poorly correlated | N/A | ||
| TSNDF - BGLAF | 3% Poorly correlated | +2.68% | ||
More | ||||